Thymosin alpha 1: biological activities, applications and genetic engineering production.

Juan Li,Chun Hui Liu,Feng Shan Wang
DOI: https://doi.org/10.1016/j.peptides.2010.07.026
IF: 3.867
2010-01-01
Peptides
Abstract:Thymosin alpha 1 (T alpha 1) a 28-amino acid peptide was first described and characterized from calf thymuses in 1977 This peptide can enhance T-cell dendritic cell (DC) and antibody responses modulate cytokines and chemokines production and block steroid-induced apoptosis of thymocytes Due to its pleiotropic biological activities Tat has gained increasing Interest in recent years and has been used for the treatment of various diseases in clinic Accordingly there is an increasing need for the production of this peptide So far T alpha 1 used in clinic is synthesized using solid phase peptide synthesis Here we summarize the genetic engineering methods to produce Tal using prokaryotic or eukaryotic expression systems The effectiveness of these biological products in increasing the secretion of cytokines and in promoting lymphocyte proliferation were investigated in vitro studies This opens the possibility for biotechnological production of T alpha 1 for the research and clinical applications (C) 2010 Elsevier Inc All rights reserved
What problem does this paper attempt to address?